Therefore, we hypothesized that simultaneous targeting by the mitochondrial complex I inhibitor and the TET1-mediated immune modulator CK2α may have additive or synergistic effects on ovarian cancer cell growth inhibition. Here, TET1 is linked to ovarian cancer.